LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

LLY

1,007.5

-0.79%↓

JNJ

230.78

+0.16%↑

ABBV

210.82

+1.12%↑

UNH

398.96

-0.39%↓

AZN

184.93

-1.48%↓

Home・Aktien・Pliant Therapeutics Inc
Search

Pliant Therapeutics Inc

Geschlossen

1.15 -2.54

Neutral

Kursupdate 14. Mai 2026, 19:55 UTC

BuySell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.1400000000000001

Max

1.17

Schlüsselkennzahlen

By Trading Economics

Einkommen

3.5M

-20M

EPS

-0.32

Angestellte

49

EBITDA

6.6M

-22M

Empfehlungen

By TipRanks

Empfehlungen

Neutral

12-Monats-Prognose

+128.21% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

14. Mai 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-6.8M

74M

Vorheriger Eröffnungskurs

3.69

Vorheriger Schlusskurs

1.15

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

1.43 / 1.6 Unterstützung & Widerstand

Pliant Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Mai 2026, 22:54 UTC

Ergebnisse

Xero Lifts Annual Earnings 18%, Flags More Growth Ahead

DJ

Lesen

13. Mai 2026, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Lesen

13. Mai 2026, 23:51 UTC

Market Talk

Australian Consumer Spending Is Holding Up; RBA Watching -- Market Talk

DJ

Lesen

13. Mai 2026, 23:45 UTC

Market Talk

Nikkei May Rise After Overnight U.S. Tech Gains -- Market Talk

DJ

Lesen

13. Mai 2026, 23:45 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Lesen

13. Mai 2026, 23:17 UTC

Ergebnisse

Samsung Fire & Marine Insurance 1Q Net Profit Beat FactSet-Compiled Consensus

DJ

Lesen

13. Mai 2026, 23:16 UTC

Ergebnisse

Samsung Fire & Marine Insurance 1Q Net KRW635.22B Vs. Net KRW609.03B >000810.SE

DJ

Lesen

13. Mai 2026, 23:15 UTC

Ergebnisse

Samsung Fire & Marine Insurance 1Q Oper Pft KRW861.13B Vs. Pft KRW792.36B >000810.SE

DJ

Lesen

13. Mai 2026, 23:14 UTC

Ergebnisse

Samsung Fire & Marine Insurance 1Q Rev KRW6.676T Vs. KRW6.106T >000810.SE

DJ

Lesen

13. Mai 2026, 23:02 UTC

Market Talk
Ergebnisse

Cisco Product Demand Climbing Even Without Hyperscalers -- Market Talk

DJ

Lesen

13. Mai 2026, 22:59 UTC

Market Talk
Ergebnisse

Cisco Boosted by Tech Infrastructure Upgrade Cycle -- Market Talk

DJ

Lesen

13. Mai 2026, 22:24 UTC

Ergebnisse

Xero FY U.S. Organic Revenue Growth 30%>XRO.AU

DJ

Lesen

13. Mai 2026, 22:23 UTC

Ergebnisse

Xero FY International Organic Revenue Growth 25%>XRO.AU

DJ

Lesen

13. Mai 2026, 22:23 UTC

Ergebnisse

Xero FY International Revenue Growth 47%>XRO.AU

DJ

Lesen

13. Mai 2026, 22:22 UTC

Ergebnisse

Xero FY Australia, New Zealand Revenue Up 18% on Year >XRO.AU

DJ

Lesen

13. Mai 2026, 22:19 UTC

Ergebnisse

Xero FY Australia, New Zealand Revenue Up 17% in Constant Currency>XRO.AU

DJ

Lesen

13. Mai 2026, 22:19 UTC

Ergebnisse

Xero FY Net Customer Additions 506,000 Vs. 254,000>XRO.AU

DJ

Lesen

13. Mai 2026, 22:18 UTC

Ergebnisse

Xero FY Rule of 40: 48.5% Vs. 44.3%>XRO.AU

DJ

Lesen

13. Mai 2026, 22:16 UTC

Ergebnisse

Xero: Ebitda Guidance Includes NZD55M of Incremental U.S. Brand Spend>XRO.AU

DJ

Lesen

13. Mai 2026, 22:15 UTC

Ergebnisse

Xero Expects FY27 Adjusted Ebitda of NZD860M-NZD920M>XRO.AU

DJ

Lesen

13. Mai 2026, 22:15 UTC

Ergebnisse

Xero Expects FY27 Operating Revenue of NZD3.62B-NZD3.73B>XRO.AU

DJ

Lesen

13. Mai 2026, 22:13 UTC

Ergebnisse

Xero FY Operating Expenses 70.5% of Operating Revenue Vs. 71.8%>XRO.AU

DJ

Lesen

13. Mai 2026, 22:12 UTC

Ergebnisse

Xero FY Free Cash Flow NZD554.0M Vs. NZD506.7M>XRO.AU

DJ

Lesen

13. Mai 2026, 22:11 UTC

Ergebnisse

Xero FY Adjusted Ebitda NZD757.4M Vs. NZD641.8M>XRO.AU

DJ

Lesen

13. Mai 2026, 22:11 UTC

Ergebnisse

Xero FY Ebitda NZD789.5M Vs. NZD638.5M>XRO.AU

DJ

Lesen

13. Mai 2026, 22:10 UTC

Ergebnisse

Xero Did Not Declare a Dividend>XRO.AU

DJ

Lesen

13. Mai 2026, 22:10 UTC

Ergebnisse

Xero FY Rev NZD2.75B Vs. NZD2.10B >XRO.AU

DJ

Lesen

13. Mai 2026, 22:09 UTC

Ergebnisse

Xero FY Net NZD167.4M Vs. Net NZD227.8M >XRO.AU

DJ

Lesen

13. Mai 2026, 22:00 UTC

Ergebnisse

Cisco to Shed Jobs for All-In AI Push -- Update

DJ

Lesen

13. Mai 2026, 21:11 UTC

Ergebnisse

Cisco Earnings and Revenue Beat Estimates on Strong AI Demand. Its Shares Surge. -- Barrons.com

DJ

Lesen

Peer-Vergleich

Kursveränderung

Pliant Therapeutics Inc Prognose

Kursziel

By TipRanks

128.21% Vorteil

12-Monats-Prognose

Durchschnitt 2.67 USD  128.21%

Hoch 3 USD

Tief 2 USD

Basierend auf 5 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pliant Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Neutral

5 ratings

1

Buy

4

Halten

0

Sell

Basierend auf 5 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Pliant Therapeutics Inc – Dist abgegeben haben.

Technischer Score

By Trading Central

1.43 / 1.6Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Mittelfristig

Bearish Evidence

Recent bearish events outweigh bullish events.

Langfristig

Weak Bearish Evidence

There is one bearish event.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Andere Aktien aus dem Sektor

LLY

Eli Lilly and Co.

1,007.5

↓-0.79%

JNJ

Johnson and Johnson

230.78

↑ +0.16%

ABBV

AbbVie Inc

210.82

↑ +1.12%

UNH

UnitedHealth Group Inc

398.96

↓-0.39%

AZN

AstraZeneca PLC

184.93

↓-1.48%
help-icon Live chat